检索结果 - Jan Cools

Refine Results
  1. 1
    The genetics and molecular biology of T-ALL

    The genetics and molecular biology of T-ALL 由 Tiziana Girardi, Carmen Vicente, Jan Cools, Kim De Keersmaecker

    出版 2017
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  2. 2
    The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11)

    The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11) 由 Bartosz Wasąg, Els Lierman, Mira Meeus, Jan Cools, Peter Vandenberghe

    出版 2011
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Molecular Mechanisms Underlying FIP1L1-PDGFRA–Mediated Myeloproliferation

    Molecular Mechanisms Underlying FIP1L1-PDGFRA–Mediated Myeloproliferation 由 Miranda Buitenhuis, Liesbeth P. Verhagen, Jan Cools, Paul J. Coffer

    出版 2007
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases

    Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases 由 Els Lierman, Sanne Smits, Jan Cools, Barbara Dewaele, Maria Dębiec‐Rychter, Peter Vandenberghe

    出版 2012
    获取全文
    Carta
    加到收藏夹
    Saved in:
  5. 5
    The ability of sorafenib to inhibit oncogenic PDGFR and FLT3 mutants and overcome resistance to other small molecule inhibitors

    The ability of sorafenib to inhibit oncogenic PDGFR and FLT3 mutants and overcome resistance to other small molecule inhibitors 由 Els Lierman, Idoya Lahortiga, Helen Van Miegroet, Nicole Mentens, Peter Marynen, Jan Cools

    出版 2007
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management

    The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management 由 Jason Gotlib, Jan Cools, James Malone, Stanley L. Schrier, D. Gary Gilliland, Steven Coutré

    出版 2003
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  7. 7
    The NPM-ALK and the ATIC-ALK Fusion Genes Can Be Detected in Non-Neoplastic Cells

    The NPM-ALK and the ATIC-ALK Fusion Genes Can Be Detected in Non-Neoplastic Cells 由 Brigitte Maes, Vera Vanhentenrijk, Iwona Włodarska, Jan Cools, Benjamin Peeters, Peter Marynen, Christiane De Wolf‐Peeters

    出版 2001
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin's lymphoma and T-cell non-Hodgkin's lymphoma

    Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin's lymphoma and T-cell non-Hodgkin's lymphoma 由 M. Kleppe, Thomas Tousseyn, Eva Geissinger, Zeynep Kalender Atak, Stein Aerts, Andreas Rosenwald, Iwona Włodarska, Jan Cools

    出版 2011
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Prediction of Resistance to Small Molecule FLT3 Inhibitors

    Prediction of Resistance to Small Molecule FLT3 Inhibitors 由 Jan Cools, Nicole Mentens, Pascal Furet, Doriano Fabbro, Jennifer Clark, James D. Griffin, Peter Marynen, D. Gary Gilliland

    出版 2004
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Evidence for position effects as a variantETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13)

    Evidence for position effects as a variantETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13) 由 Jan Cools, Nicole Mentens, María D. Odero, Pieter J. Peeters, Iwona Włodarska, Michel Delforge, Anne Hagemeijer, Peter Marynen

    出版 2002
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518

    Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518 由 Jennifer Clark, Jan Cools, David P. Curley, Jin‐Chen Yu, Nathalie A. Lokker, Neill A. Giese, D. Gary Gilliland

    出版 2004
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness

    Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor progno... 由 Amy D. Klion, Pierre Noël, Cem Akin, Melissa Law, D. Gary Gilliland, Jan Cools, Dean D. Metcalfe, Thomas B. Nutman

    出版 2003
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    The Long Non-coding RNA Flatr Anticipates Foxp3 Expression in Regulatory T Cells

    The Long Non-coding RNA Flatr Anticipates Foxp3 Expression in Regulatory T Cells 由 Aleksandra Brajic, Dean Franckaert, Oliver T. Burton, Simon Bornschein, A. Calvanese, Sofie Demeyer, Jan Cools, James Dooley, Susan Schlenner, Adrian Liston

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor–Associated PDGFRAD842V Mutation

    Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor–Associated PDGFRAD842V Mutation 由 Barbara Dewaele, Bartosz Wasąg, Jan Cools, Raf Sciot, Hans Prenen, Peter Vandenberghe, Agnieszka Woźniak, Patrick Schöffski, Peter Marynen, Maria Dębiec‐Rychter

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant

    Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant 由 Els Lierman, Cedric Folens, Elizabeth H. Stover, Nicole Mentens, Helen Van Miegroet, Werner Scheers, Marc Boogaerts, Peter Vandenberghe, Peter Marynen, Jan Cools

    出版 2006
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    Targeting PIM Kinases Impairs Survival of Hematopoietic Cells Transformed by Kinase Inhibitor–Sensitive and Kinase Inhibitor–Resistant Forms of Fms-Like Tyrosine Kinase 3 and BCR/ABL

    Targeting PIM Kinases Impairs Survival of Hematopoietic Cells Transformed by Kinase Inhibitor–Sensitive and Kinase Inhibitor–Resistant Forms of Fms-Like Tyrosine Kinase 3 and BCR/A... 由 Myriam Adam, Vanda Pogac̆ić, Marina Bendit, Richard Chappuis, Martijn C. Nawijn, Justus Duyster, Casey Fox, Craig B. Thompson, Jan Cools, Juerg Schwaller

    出版 2006
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane domain of PDGFRα and is FIP1L1-independent

    Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane domain of PDGFRα and is FIP1L1-independent 由 Elizabeth H. Stover, Jing Chen, Cedric Folens, Benjamin H. Lee, Nicole Mentens, Peter Marynen, Ifor R. Williams, D. Gary Gilliland, Jan Cools

    出版 2006
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    In vitro validation of -secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia

    In vitro validation of -secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia 由 Kim De Keersmaecker, Idoya Lahortiga, Nicole Mentens, Cedric Folens, Leander Van Neste, Sofie Bekaert, Peter Vandenberghe, María D. Odero, Peter Marynen, Jan Cools

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions

    ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions 由 Katrien Van Roosbroeck, Jan Cools, Daan Dierickx, José Thomas, Peter Vandenberghe, Michel Stul, Jan Delabie, Chris De Wolf‐Peeters, Peter Marynen, Iwona Włodarska

    出版 2010
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32)

    Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32) 由 Kim De Keersmaecker, Carlos Graux, María D. Odero, Nicole Mentens, Riet Somers, Johan Maertens, Iwona Włodarska, Peter Vandenberghe, Anne Hagemeijer, Peter Marynen, Jan Cools

    出版 2005
    获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: